Other substances

TNX-1800

COVID-19 candidate vaccine

Phase of research

Potential treatment - theoretical effect

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

TNX-1800 is a candidate vaccine being developed by Tonix Pharma/Southern Research. It is a Horsepox vector expressing the S protein type of candidate vaccine. It is based on the Replicating Viral Vector platform, which is also used for non-COVID-19 candidates, such as Smallpox and monkeypox. Currently, this COVID-19 candidate vaccine is in pre-clinical evaluation.

TNX-1800 on TonixPharmaceuticals

 

Supporting references

Link Tested on Impact factor Notes Publication date
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020
in vitro Mar/26/2020
Export (.csv)